Oncolytic Virus Therapy for Brain Tumors: Mechanisms of Action, Research Progress, and Future Prospects

Brain tumors, particularly glioblastoma (GBM), remain among the most challenging diseases in neuro-oncology. Despite continuous advances in surgery, radiotherapy, chemotherapy, and targeted therapies, patients with GBM still face high recurrence rates and poor prognosis.

In recent years, novel treatment strategies centered on immunotherapy have attracted increasing attention. Among them, oncolytic virus (OV) therapy has emerged as one of the most promising approaches for brain tumors due to its dual ability to directly destroy tumor cells while simultaneously stimulating anti-tumor immune responses.

Why are oncolytic viruses considered a potential breakthrough in overcoming the treatment challenges of brain tumors? What progress has been made so far, and what does the future hold? In this article, Hong Kong DengYueMed provides a comprehensive overview.

Why Does Brain Tumor Treatment Remain So Challenging?

The difficulty in treating brain tumors largely stems from their unique biological characteristics.

First, the blood-brain barrier (BBB) limits the delivery of many therapeutic agents into brain tissue, making it difficult for certain targeted drugs and biologics to reach effective concentrations.

Second, brain tumors are highly heterogeneous. Different populations of tumor cells may coexist within the same tumor, responding differently to treatment and contributing to drug resistance and recurrence.

In addition, brain tumors often possess a strongly immunosuppressive tumor microenvironment. Large numbers of immunosuppressive cells accumulate around the tumor, limiting the activity of T cells and other immune cells. This is one of the major reasons why conventional immune checkpoint inhibitors have shown limited efficacy in GBM.

Currently, the standard first-line treatment for glioblastoma consists of maximal safe surgical resection followed by radiotherapy combined with temozolomide chemotherapy. However, most patients eventually experience disease recurrence, highlighting the urgent need for new therapeutic strategies.

What Is Oncolytic Virus Therapy?

Oncolytic virus therapy is a novel form of immunotherapy that uses naturally occurring or genetically engineered viruses to selectively infect and destroy cancer cells.

Unlike common viruses, oncolytic viruses are designed to preferentially replicate within tumor cells while causing minimal damage to normal tissues.

The therapeutic process generally involves three key steps:

1.  The virus enters tumor cells.

2.  It replicates extensively within the tumor cells, leading to cell lysis.

3.  Newly released viral particles and tumor antigens stimulate the immune system, triggering immune responses against remaining cancer cells.

As a result, oncolytic viruses not only directly eliminate tumor cells but also transform immunologically "cold" tumors into tumors that are more recognizable by the immune system.

How Do Oncolytic Viruses Overcome the Challenges of Brain Tumor Treatment?

1. Direct Destruction of Tumor Cells

The primary function of oncolytic viruses is to selectively infect tumor cells.

Because tumor cells often have impaired antiviral defense mechanisms and abnormal cell-cycle regulation, viruses can replicate efficiently within them, eventually causing tumor cell lysis and releasing new viral particles that continue infecting neighboring cancer cells.

This self-amplifying mechanism distinguishes oncolytic viruses from conventional therapies that act only once.

2. Activation of Anti-Tumor Immune Responses

Recent studies suggest that the greatest advantage of oncolytic viruses lies not only in their direct tumor-killing ability but also in their capacity to remodel the tumor immune microenvironment.

When tumor cells are destroyed, they release tumor-associated antigens and danger signals that promote antigen uptake by dendritic cells and activate T cells, ultimately inducing systemic anti-tumor immunity.

This means that even if not every tumor cell is directly infected by the virus, the immune system may continue recognizing and eliminating residual cancer cells.

3. Synergy with Other Cancer Therapies

Growing evidence indicates that oncolytic viruses are not intended to replace existing therapies but rather to serve as an important component of combination treatment strategies.

Current research focuses on combining oncolytic viruses with:

● PD-1/PD-L1 immune checkpoint inhibitors

● Radiotherapy to enhance tumor immunogenicity

● CAR-T cell therapy to improve immune cell infiltration

● Chemotherapy to maximize overall treatment efficacy

These multimodal combination strategies are considered a major direction for the future treatment of brain tumors.

4. Improved Precision Through Local Administration

Due to the unique anatomy of the brain, most oncolytic viruses for brain tumors are currently administered through intratumoral injection or intraoperative injection rather than intravenous infusion.

This localized delivery approach increases viral concentration within the tumor while reducing systemic exposure and treatment-related adverse effects.

Representative Oncolytic Viruses for Brain Tumors

In recent years, several oncolytic viruses have entered clinical development for brain tumors.

Although these therapies differ in their design and development strategies, they all share the common goal of improving tumor control and extending patient survival.

What Challenges Still Remain?

Despite its promising potential, oncolytic virus therapy still faces several important challenges.

First, treatment responses vary considerably among patients, and reliable biomarkers for predicting treatment benefit have not yet been established.

Second, because of the complex structure of brain tissue, viral spread within tumors remains limited, making it necessary to develop more effective delivery strategies.

In addition, the optimal administration route, dosage, treatment timing, and combination regimens all require validation through larger clinical trials.

Finally, although encouraging results have been reported, most oncolytic virus therapies for brain tumors are still under clinical investigation, and additional high-quality evidence is needed to confirm their long-term efficacy and safety.

Future Directions

With continued advances in viral engineering, immunotherapy, and precision medicine, oncolytic viruses are expected to play an increasingly important role in brain tumor treatment.

Future research is expected to focus on:

● Developing safer and more precise next-generation engineered oncolytic viruses

● Combining oncolytic viruses with immune checkpoint inhibitors

● Integrating oncolytic viruses with CAR-T cell therapy and cancer vaccines

● Using artificial intelligence and molecular profiling to identify patients most likely to benefit

● Conducting more international multicenter Phase III clinical trials to generate robust clinical evidence

As these efforts continue, oncolytic viruses are expected to become an integral part of comprehensive brain tumor treatment, offering new therapeutic options for patients with recurrent and difficult-to-treat brain tumors.

Conclusion

Brain tumors, particularly glioblastoma, remain one of the greatest challenges in modern neuro-oncology. Through their ability to directly destroy tumor cells, stimulate anti-tumor immune responses, and work synergistically with multiple treatment modalities, oncolytic viruses have become one of the most promising areas of brain tumor research worldwide.

Although most therapies are still in clinical development or early clinical application, existing studies have demonstrated encouraging therapeutic potential. As advances continue in engineered viral technologies, combination immunotherapy, and precision medicine, oncolytic virus therapy is expected to provide more effective treatment options for patients with brain tumors and help usher in a new era of brain tumor immunotherapy.

For more information about the latest advances in tumor treatment, innovative medicines, or related pharmaceutical supply solutions, feel free to contact DengYueMed.